Abstract
Background Chronic cannabis use can present with cognitive impairments that resemble ADHD. Our objective was to determine if medical cannabis (MC) legalization increased prescription stimulant distribution.
Methods We extracted distribution of methylphenidate, amphetamine, and lisdexamfetamine from the Drug Enforcement Administration’s comprehensive database for 2006 to 2021 and compared the three-year population-corrected slopes of stimulant distribution before and after MC program implementation.
Results We found a very large main effect of time (p≤0.001), but, contrary to the hypothesis not states’ MC sales status, on slopes of distribution (p=0.391). There was a significant and large interaction effect of time and MC sales status on slopes of distribution (p≤0.001).
Discussion These findings suggest that medical cannabis program legalization may have contributed to some states having more rapid increases in Schedule II stimulant distribution rates over time.
Competing Interest Statement
Disclosures: Research of BJP is supported by the Pennsylvania Academic Clinical Research Center. Prior (2019 to 2021) osteoarthritis research was supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: BJP’s research is supported by the Pennsylvania Academic Clinical Research Center. Prior (2019 – 2021) osteoarthritis research was supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Data Availability
All data produced in the present study are available upon reasonable request to the authors and available as supplemental material on medrxiv.org
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
